Drugs / Expanded Activated Lymphocytes (EAL)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05213637 | Apr 2018 → Jun 2022 | hepatocellular carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded Activated Lymphocytes (EAL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05213637 ↗ |
| Modality | Cell therapy | “EAL are ex vivo expanded and activated lymphocytes comprising mainly CD8+ T cells derived from patients' peripheral blood.” NCT05213637 ↗ |